Skip to main content
Gregg Fonarow, MD, Cardiology, Los Angeles, CA, Ronald Reagan UCLA Medical Center

GreggCurtisFonarowMD

Cardiology Los Angeles, CA

Heart Failure & Transplantation, Preventive Cardiology

Professor of Medicine, UCLA

Dr. Fonarow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Fonarow's full profile

Already have an account?

  • Office

    UCLA Medical Center
    100 Medical Plaza, Suite 630
    Los Angeles, CA 90095
    Phone+1 310-825-8816
    Fax+1 310-825-8816
  • Is this information wrong?

Summary

  • Dr. Gregg Fonarow is a cardiologist in Los Angeles, CA and is affiliated with Ronald Reagan UCLA Medical Center. He received his medical degree from David Geffen School of Medicine at UCLA and has been in practice 30 years. He specializes in heart failure & transplantation, quality of care, and preventive cardiology and is experienced in general cardiology, preventive cardiology, heart failure, and critical care medicine. He is co-Chief of the UCLA Division of Cardiology.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Cardiovascular Disease, 1990 - 1993
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1987 - 1990
  • David Geffen School of Medicine at UCLA
    David Geffen School of Medicine at UCLAClass of 1987

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1988 - 2026
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • Chairman's Award American Heart Association, 2017
  • Fellow Heart Failure Society of America Heart Failure Society of America, 2015
  • Distinguished Clinical Research Award Clinical Research Forum, 2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Expediting the Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure—There Is No Time for Delay  
    Gregg C Fonarow, Clyde W Yancy, JAMA Cardiology
  • National Trends in Heart Failure Hospitalizations and Readmissions from 2010 to 2017  
    Manyoo A Agarwal, Gregg C Fonarow, Boback Ziaeian, JAMA Cardiology
  • Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical Practice  
    Muthiah Vaduganathan, Javed Butler, Paul A Heidenreich, Michelle M Kittleson, Anjali Tiku Owens, Pamela N Peterson, Clyde W Yancy, Gregg C Fonarow, JAMA Cardiology
  • Join now to see all

Lectures

  • Hospital Re-Admission Measure Is the Right Quality Measure in Heart Failure 
    2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019

Authored Content

  • VERTIS CV Trial: Heterogeneity in Clinical Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Type II Diabetes?September 2020
  • Cost-Effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure with Reduced Ejection FractionAugust 2020
  • Cost-Effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure with Reduced Ejection FractionAugust 2020
  • Coronavirus Disease 2019 (COVID-19) and the Heart—Is Heart Failure the Next Chapter?July 2020
  • Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients with Acute Ischemic StrokeJune 2020
  • Association of Coronavirus Disease 2019 (COVID-19) with Myocardial Injury and MortalityMarch 2020
  • Association of Coronavirus Disease 2019 (COVID-19) with Myocardial Injury and MortalityMarch 2020
  • Association of Coronavirus Disease 2019 (COVID-19) with Myocardial Injury and MortalityMarch 2020
  • Association of Coronavirus Disease 2019 (COVID-19) with Myocardial Injury and MortalityMarch 2020
  • 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction A Report of the American College of Cardiology Task Force on Expert Consensus Decision PathwaysJanuary 2018
  • 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection FractionDecember 2017
  • 2017 AHA/ACC Clinical Performance and Quality Measures for Adults with ST-Elevation and Non–ST-Elevation Myocardial Infarction A Report of the American College of Cardiology/American Heart Association Task Force on Performance MeasuresOctober 2017
  • Join now to see all

Press Mentions

  • Large Study Supports Less Invasive Way to Treat ‘Leaky’ Heart Valves
    Large Study Supports Less Invasive Way to Treat ‘Leaky’ Heart ValvesMay 24th, 2023
  • New ‘E-tattoo’ Is Worn on Chest to Track Your Heart Health
    New ‘E-tattoo’ Is Worn on Chest to Track Your Heart HealthMay 3rd, 2023
  • Study Finds Equitable Heart Failure Care, but Challenges Remain
    Study Finds Equitable Heart Failure Care, but Challenges RemainApril 19th, 2023
  • Join now to see all

Professional Memberships

Hospital Affiliations